The U.S. Food and Drug Administration (FDA) is providing this communication to increase awareness of recent updates to the product labeling of capecitabine (Xeloda) and fluorouracil (5-FU) related to risks associated with dihydropyrimidine dehydrogenase (DPD) deficiency. All healthcare providers sho
Similar Posts
Supreme Deli LLC Voluntarily Recalls Boar’s Head Pecorino Romano Cheese Because of Possible Health Risk
Supreme Service Solutions LLC. (dba Supreme Deli) is assisting in a recall for items purchased from Boar’s Head Brand’s supplier of pecorino romano cheese. Ambriola Company, has issued a recall for select SKUs of pecorino romano cheese products, including two products they produce under the Boar’s HWalgreen Company – 662158 – 12/19/2025
Failure to Register and ListAdvancing Real-World Evidence Program
Advancing Real-World Evidence ProgramPOSTPONED – 17th Annual Sentinel Initiative Public Workshop – 11/06/2025
The U.S. Food and Drug Administration, under a cooperative agreement with the Duke-Margolis Institute for Health Policy, is hosting the 16th Annual Sentinel Initiative Public Workshop on November 6, 2025October 10, 2024: Meeting of the Cardiovascular and Renal Drugs Advisory Committee – 10/10/2024
The Committee will discuss new drug application (NDA) 215244, for elamipretide hydrochloride injection, submitted by Stealth BioTherapeutics Inc., for the treatment of Barth Syndrome.Global Generic Drug Affairs
FDA’s Office of Generic Drugs (OGD) ensures, through a scientific and regulatory process, that Americans have access to safe, effective, and high-quality generic drugs.